Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a biotechnology company with a sole focus on developing innovative therapies for severe autoimmune and inflammatory disorders. Their lead program, EQ504, has shown promising results in pre-clinical studies by decreasing pathogenic IL-17A while increasing protective IL-22 in both healthy and UC patient cells. Upcoming catalysts, including a second poster on EQ504's epithelial repair and Phase 1 initiation, could continue to drive positive momentum. However, there are also potential risks, including competition from other AHR agonist drugs and the need for additional financing beyond Phase 1. Overall, Equillium's innovative approach and strong pipeline make it a promising investment opportunity.

Bears say

Equillium is a clinical-stage biotechnology company that faces typical risks associated with this industry, such as clinical trials, safety concerns, financing, and competitive challenges. These risks could impede the company's progress and could negatively impact its stock price. Additionally, regulatory risk is a concern as the company's biomarker endpoints in Phase 1 may not translate to clinical efficacy endpoints in later phases, hindering the path to approval. Overall, it may be difficult for Equillium to achieve success, and its stock may not perform well as a result.

Equillium Inc (EQ) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of May 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.